Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) insider Jo Ann Beltramello sold 1,219 shares of the stock in a transaction on Monday, July 27th. The stock was sold at an average price of $30.00, for a total value of $36,570.00. Following the transaction, the insider now owns 57,106 shares of the company’s stock, valued at $1,713,180. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
Jo Ann Beltramello also recently made the following trade(s):
- On Wednesday, July 8th, Jo Ann Beltramello sold 4,094 shares of Momenta Pharmaceuticals stock. The shares were sold at an average price of $34.35, for a total transaction of $140,628.90.
- On Tuesday, June 30th, Jo Ann Beltramello sold 6,812 shares of Momenta Pharmaceuticals stock. The stock was sold at an average price of $35.10, for a total transaction of $239,101.20.
- On Thursday, June 18th, Jo Ann Beltramello sold 4,122 shares of Momenta Pharmaceuticals stock. The shares were sold at an average price of $34.90, for a total transaction of $143,857.80.
Shares of Momenta Pharmaceuticals stock opened at $30.32 on Friday. The stock’s fifty day simple moving average is $33.98 and its 200 day simple moving average is $30.72. The company has a market capitalization of $3.57 billion, a PE ratio of -10.83 and a beta of 1.51. Momenta Pharmaceuticals, Inc. has a 12 month low of $10.71 and a 12 month high of $39.88.
Several analysts have recently weighed in on the stock. Piper Sandler reaffirmed a “buy” rating and set a $45.00 price objective on shares of Momenta Pharmaceuticals in a report on Wednesday. HC Wainwright boosted their price objective on Momenta Pharmaceuticals from $46.00 to $50.00 and gave the stock a “buy” rating in a research note on Wednesday. SunTrust Banks upgraded shares of Momenta Pharmaceuticals to a “buy” rating in a research report on Thursday, June 18th. Wells Fargo & Co upped their target price on shares of Momenta Pharmaceuticals from $40.00 to $48.00 and gave the stock an “overweight” rating in a research report on Monday, June 15th. Finally, Cantor Fitzgerald raised their price target on shares of Momenta Pharmaceuticals from $30.00 to $38.00 and gave the company a “neutral” rating in a report on Tuesday, June 16th. They noted that the move was a valuation call. Four analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $43.44.
Several institutional investors have recently added to or reduced their stakes in the company. FDx Advisors Inc. bought a new stake in shares of Momenta Pharmaceuticals during the first quarter worth $37,000. GQ Asset Management LLC acquired a new position in Momenta Pharmaceuticals in the 1st quarter worth $53,000. US Bancorp DE increased its holdings in Momenta Pharmaceuticals by 1,036.0% during the 1st quarter. US Bancorp DE now owns 2,113 shares of the biotechnology company’s stock worth $57,000 after purchasing an additional 1,927 shares in the last quarter. Mutual of America Capital Management LLC raised its stake in shares of Momenta Pharmaceuticals by 23.7% in the 1st quarter. Mutual of America Capital Management LLC now owns 5,018 shares of the biotechnology company’s stock valued at $136,000 after purchasing an additional 963 shares during the period. Finally, Nisa Investment Advisors LLC raised its stake in shares of Momenta Pharmaceuticals by 26.6% in the 1st quarter. Nisa Investment Advisors LLC now owns 6,040 shares of the biotechnology company’s stock valued at $164,000 after purchasing an additional 1,270 shares during the period. Institutional investors own 96.92% of the company’s stock.
About Momenta Pharmaceuticals
Momenta Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG Fc regions joined to maximize activity; and M254, a hyper-sialylated immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy.
Featured Story: Closed-End Mutual Funds
Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.